cyrilzakka/clinical-trials huggingface dataset:
Study on Doppler Ultrasound Measurement of Changes in Uterine Artery Blood Flow in Normal First Trimester Pregnancies and Its Prediction on Abortion

Objective:To explore the study of Doppler ultrasound in first trimester pregnancies to measure the change of uterine artery blood flow in normal pregnancies and the prediction on abortion, which provides a certain reference for the change trend of uterine artery blood flow in normal first trimester pregnancies and the prediction of Doppler ultrasound measurement in abortion.

Method:Pregnant women who underwent natural conception and single birth prenatal examination in the Obstetrics Department of the Second Affiliated Hospital of Wenzhou Medical University from October 1, 2023 to December 31, 2025 were selected as the study population. Eligible women were preliminarily screened according to the inclusion conditions of the study objects, and basic information of women in each group was compared: Maternal age, gestational time, birth time, gestational week, abortion history, maternal BMI, maternal MAP, smoking status, serum HCG, subchorionic hematoma, fetal bradycardia, left and right uterine aorta pulse index (PI), resistance index (RI) and systolic/diastolic ratio (S/D), etc. To investigate the effect of Doppler ultrasonography on the measurement of uterine artery blood flow in normal pregnancy and the prediction of abortion.


Eligibility Criteria:
Healthy pregnant women Group

Inclusion Criteria:

1. Intrauterine pregnancy sac and cardiac activity were confirmed by ultrasound examination at 6 weeks;
2. Complete maternal clinical data;

Exclusion Criteria:

1. The level of chorionic gonadotropin (HCG) was static or decreased by ultrasonography;
2. multiple pregnancy;
3. Patients with congenital uterine malformations, uterine fibroids and any other uterine disease;
4. Patients who have chronic diseases or are receiving chronic treatment.

Pregnant women with recurrent pregnancy loss Group

Inclusion Criteria:

1. Intrauterine pregnancy sac and cardiac activity were confirmed by ultrasound examination at 6 weeks;
2. Complete maternal clinical data;
3. There has been a history of spontaneous abortion with the same sexual partner for two or more consecutive times;

Exclusion Criteria:

1. The level of chorionic gonadotropin (HCG) was static or decreased by ultrasonography;
2. multiple pregnancy;
3. Patients with congenital uterine malformations, uterine fibroids and any other uterine disease;
4. Patients who have chronic diseases or are receiving chronic treatment.
Effect of Instability on Power and Speed in Bench Press

The aim of this study was to analyse and compare the speed and power parameters in bench press training in different degrees of instability: 1) stable (PBE), 2) with asymmetric load (PBA), 3) with oscillating load (PBO), 4) on fitball (PBF) and 5) on bosu (PBB). For this purpose, 20 male subjects (10 trained and 10 untrained) with specific experience in training under unstable conditions were evaluated with respect to mean propulsive velocity (MPV), maximum velocity (MV) and power (POT) with different types of external load: low load (40% of 1RM), medium load (60% of 1RM) and high load (80% of 1RM) in each condition.

Therefore, the aim of this study was to analyse the effect of different degrees of instability on power and speed of execution in the bench press exercise. For the design of this quasi-experimental research, with an ad hoc protocol, an intersubject comparison was used in 5 different conditions. 20 male participants were grouped into two groups based on their previous experience with unstable training and volunteered for this study. Expert group (n= 10; 23.70 ± 4.30 years; 81.40 ± 9.67 kg; 179.50 ± 8.95 cm; 3.5 ± 4.10 years of strength training experience; 9 ± 10.60 months of unstable training experience) Novice group (n= 10; 25.60 ± 6.50 years; 77.80 ± 4.44 kg; 176.40 ± 2.80 cm; 3.40 ± 1.96 years of strength training experience; 0.90 ± 0.99 months of unstable training experience). Subjects with no experience in training with unstable loads (having implemented unstable loads in their training at some point) or current or recent injuries (within the last 6 months) that caused them to alter their normal physical activity were excluded from this study. This study was in accordance with the Declaration of Helsinki (2013). All participants gave written informed consent prior to the study.

Subjects performed the bench press exercise by assessing mean propulsive velocity and power with 3 different loads for each of the unstable situations: light (40% of 1RM), moderate (60% of 1RM) and high (80% of 1RM). In a familiarisation session, subjects performed the relative loads with each condition to determine their strength-velocity profiles and their optimal work percentages. In addition, an incremental load test was performed to determine the 1RM of each of the participants to determine the external load for each load percentage in each of the subjects.

Eligibility Criteria:
Inclusion Criteria:

* two years of continuous strength training experience
* a minimum of 6 months of suspended training experience

Exclusion Criteria:

* Athletes who presented pain or skeletal or neuromuscular disorder
A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.


Eligibility Criteria:
Inclusion Criteria:

* Patients who are in need of a vitrectomy.

Exclusion Criteria:

* A PVD in the study eye as assessed by the investigator using ophthalmic and alternative examination techniques.
* A history of vitrectomy in the study eye.
* A media opacity that precludes quality examination of the vitreous and fundus in the study eye.
Quality of Recovery in the Post-anesthesia Care Unit

This prospective observational study aims to identify the minimal clinically important difference of the QoR-PACU2 questionnaire. In addition, this study aims to assess the correlation between self-reported quality of postoperative recovery early after surgery in the post-anesthesia care unit and postoperative recovery on the first day after surgery.


Eligibility Criteria:
Inclusion Criteria:

* elective non-cardiac surgery
* expected duration of surgery ≥60 minutes
* postoperative stay at the post-anesthesia care unit

Exclusion Criteria:

* surgery or condition requiring postoperative treatment at an intensive care unit
* inability to give informed consent/requirement of a legal guardian
The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients

To evaluate the influence of corneal-aberrations before and after the meibomian gland thermal massage treatment.

62 MGD patients treated with meibomian gland thermal massage once a week for 3 to 4 weeks were recruited.The Ocular Surface Disease Index questionnaire; tear film assessment encompassing tear meniscus height and non-invasive keratograph breakup time ; meibography score,corneal fluorescein staining; the Schirmer I test ; expressible meibomian gland, and quality ,anterior and total corneal aberrations were evaluated before and after treatment.

Eligibility Criteria:
Inclusion Criteria:

* tear break-up time (BUT) ≤10 seconds or Schirmer I test (SIT) ≤10 mm, the presence of dry eye symptoms, and fluorescein staining (FL) score \<3 points and at least one lid margin abnormality and poor meibomian gland expressibility

Exclusion Criteria:

* eyelid structure abnormal(Entropion , ectropion);
* having received any other treatment for MGD within three months
* history of ocular surgery
* contact lens use
* ocular infection
* any type of corneal scarring
Evaluation of the Repeatability and Reproducibility of Corneal Epithelial Thickness Mapping With SD-OCT

Evaluate the repeatability and reproducibility of the RTVue-XR for measuring the total corneal thickness (pachymetry), the epithelial thickness, and the stromal thickness mapping in normal subjects and corneal patients.


Eligibility Criteria:
Inclusion Criteria:

* Able and willing to provide consent.
* Able and willing to complete required exams
* History of refractive surgery, contact lens, dry eye or keratoconus for corneal patients

Exclusion Criteria:

* Unable to complete required exams
* History of refractive surgery, contact lens, dry eye or keratoconus for normal patients
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.

The purpose of the study is to evaluate the effectiveness of duloxetine in reducing urinary incontinence(leakage of urine)occurrences in women due to physical stress and leakage that occurs during a strong need(urge) to urinate.


Eligibility Criteria:
Inclusion Criteria:

* female outpatients greater than or equal to 18 years of age.
* experience episodes of urinary incontinence based on diagnostic criteria of at least 4 episodes a week with symptoms for a minimum of three months prior to start of study.
* have an educational level and degree of understanding English.
* are free of urinary tract infections.
* have a discreet episodes of incontinence(i.e. dry between episodes and do not continuously leak.)

Exclusion Criteria:

* have received treatment for incontinence within the last 5 years.
* suffer from severe constipation.
* currently nursing or breast feeding.
* any nervous system disease that would affect normal urinary function.
* any extension of internal organs beyond the vaginal opening.
Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery

The primary objective of this study is to determine if omega-3 polyunsaturated fatty acids reduce atrial fibrillation and other outcomes after cardiac surgery. In this placebo-controlled trial, patients undergoing elective coronary artery bypass graft surgery with or without valve repair will be treated with omega-3 polyunsaturated fatty acids perioperatively. The following hypotheses will be tested: 1. omega-3 polyunsaturated fatty acids reduces the incidence of atrial fibrillation (AF) after cardiac surgery, 2. omega-3 polyunsaturated fatty acids, administered in the perioperative period for cardiac surgery, decreases postoperative complication rates, and 3. omega-3 polyunsaturated fatty acids decrease intensive care unit and hospital length-of-stay.

Atrial fibrillation is the most common complication after bypass surgery. It is a significant burden to the healthcare system because it is associated with increased hospital costs and a longer hospital length-of-stay. Atrial fibrillation occurring after bypass surgery is associated with increased morbidity and mortality. Atrial fibrillation is also associated with an increased risk for strokes, use of potentially harmful drugs, and the need for pacemaker therapy.

This study is for patients who are undergoing elective bypass surgery. Patients who meet study criteria and who consent to participate in the study will be randomized to treatment with omega-3 fatty acids or matching corn oil placebo, prior to surgery. After surgery, treatment will continue until the primary endpoint, atrial fibrillation, is reached, or 14 days, whichever is first.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-85 years old.
* Elective coronary artery bypass (CABG) operation with or without concomitant valve surgery planned for at least 2 days after enrollment.
* Signed, documented informed consent prior to admission to the study.

Exclusion Criteria:

* Urgent or emergent bypass required to be performed \<24 hrs after screening.
* Unstable angina, requiring intervention or CABG \<24 hrs after screening.
* Decompensated congestive heart failure.
* Chronic, persistent atrial fibrillation - patient in atrial fibrillation at the time of screening or enrollment or scheduled for a maze procedure or pulmonary vein isolation at the time of surgery.
* Known sensitivity to Omacor (0mega-3 acid ethyl esters) and hypersensitivity to fish, fish products or corn oil.
* Patients requiring warfarin or Lovenox the 2 days prior to bypass surgery.
* Patients on Class I or III antiarrhythmic agents (quinidine, procainamide, disopyramide, flecainide, propafenone, moricizine, dofetilide, sotalol, amiodarone) or who have taken these drugs within 5 elimination half-lives of the drug (or within 2 months for amiodarone).
* Patients who are pregnant or nursing.
* Patients unable to provide/sign informed consent.
* Patients currently enrolled in another clinical trial without a 30 day washout period.
* Patients currently taking marine based omega-three fish oil supplements.
Validation of A&D UA-651 in Children

This study will determine if the A\&D UA-651 blood pressure monitor is valid in children.


Eligibility Criteria:
Inclusion Criteria:

* Parent permission
* Assent for participants aged 7-12
* Additional sequential selection criteria (described below)

Exclusion Criteria:

* Withdrawal of permission or assent
* Younger than 3 or older than 12 years of age
* Uncooperative participants, defined as refusing instructions from study personnel, coordinators, or observers
* Physical preclusion to taking blood pressure
* Participants who have any reference blood pressure measurement exceeding the 95th percentile plus 30mmHg for their age, sex, and height (urgent blood pressure level as defined by the American Academy of Pediatrics)
* Participants with systolic blood pressure difference of greater than 12mmHg or diastolic blood pressure difference of greater than 8mmHg between any two reference measurements

Sequential Selection Criteria:

Participants will be selected sequentially during study events. Per ISO/ESH/AAMI standards, participants must meet the following characteristics:

* at least 30% male and 30% female
* at least 1/6 using each of the three available cuff sizes (small, medium, large)
* for each cuff size, at least 40% in the upper half of the arm circumference range and at least 40% in the lower half of the arm circumference range.

If including a participant would require that additional participants be enrolled to meet the above criteria, that participant will not be included. For example, if only 2 small cuff participants are needed to complete the study, but a prospective participant would require a large cuff AND including that participant will require additional small or medium cuff participants to complete the study, then that prospective participant will not be included.
Impact of P53 and SIRT1 in Type 2 Diabetes

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

Investigating the impact of p53 and SIRT1 in the development of type 2 DM through the treatment of prediabetic individuals by either nigetella salivata or Metformin

Eligibility Criteria:
Inclusion Criteria:

* Prediabetic subjects.

Exclusion Criteria:

* Confirmed diabetes.
* Hepatic or renal impairment.
Corneal Changes After Crosslinking in Keratoconus Patients Compared to the Untreated Fellow Eye

The purpose of this retrospective study is to assess corneal changes (keratometry, pachymetry) and change in visual acuity (VA) in keratoconus patients after unilateral crosslinking treatment compared to the untreated fellow eye. The corneal measurements obtained preoperatively and 2 to 14 months postoperatively using a Pentacam rotating scheimpflug camera are analyzed. Furthermore, pre-existing or actual ocular pathology or/and ocular surgeries as potential factors involved in treatment outcome are also evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Keratoconus patients after unilateral crosslinking treatment

Exclusion Criteria:

* Morphological changes of the cornea caused be ocular infection or trauma (e.g. corneal scarring)
* Other pre-existing corneal surgery (e.g. corneal transplantation, implantation of intrastromal corneal ring segments)
A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion, derive benefit from continued treatment.


Eligibility Criteria:
Key Inclusion Criteria:

* Received ARRY-371797 as treatment for a genetic dilated cardiomyopathy secondary to LMNA mutations in a clinical study sponsored by Array BioPharma.
* May, in the opinion of the Investigator, benefit from continued ARRY-371797 treatment.
* Additional criteria exist.

Key Exclusion Criteria:

* Discontinued treatment in the parent study for any reason other than study completion or Sponsor termination of the study.
* Additional criteria exist.
The Effect of Exercise Training on Balance and Functional Status in Individuals With Osteoarthritis'

The aim of this study was to evaluate and compare the effects of Clinical Pilates Exercise Training and Combined Exercise Training on balance and functional status in individuals with knee Osteoarthritis (OA).


Eligibility Criteria:
Inclusion Criteria:

* Individuals diagnosed with knee osteoarthritis II-III level according to the results of radiological evaluation by Kellgren and Lawrence

  * Individuals aged between 40 and 70 years
  * Individuals who have pain in his/her either of the knees in 3 month period and who have a VAS score of 3 or more
  * Individuals who can walk 10 meters independently (with or without ancillary device)

Exclusion Criteria:

* Individuals with Body Mass Index 35 and above
* Individuals with a history of surgery or injury involving the lower limb within the last 1 year (knee / hip endoprosthesis, post-fracture surgery, menisectomy, etc.)
* Individuals who received hyaluronic acid or corticosteroid injections in the last year
* People with severe eyesight, hearing disabilities Individuals with neurological deficit or disorder
* Individuals with regular exercise habits in the last 6 months
* Individuals with inflammatory rheumatic diseases.
Evaluating Patient Knowledge About Perioperative Neurocognitive Disorders (KNOW-PND Study)

Neurocognitive disorders remain one of the major perioperative complications. They are associated with delayed recovery, prolonged length of hospital stay and impacts on patients' quality of life. The incidence of PND ranges from 15-50%.

While several causes have been investigated, PND seems to be due to the non-resolution of an inflammatory cascade, making some patients more at risk than others. As such, major risk factors include old age and lower education levels.

As the global proportion of people aged 60 and above between 2015 and 2050 will increase from 12% to 22% and worldwide surgeries increases to \>300 million procedures per annum the incidence of perioperative neurocognitive disorders with high morbidity and mortality will go up.

In 2015, the American Society of Anesthesiologists (ASA) launched the 'Perioperative Brain Health Initiative' to increase awareness about perioperative neurocognitive disorders. (PND) While physicians seems to be more and more aware about this condition, data regarding patient awareness are not available.

An observational, single-centre, cross-sectional survey study (with initially a feasibility study) will be conducted in patients, 65 years and above undergoing elective total hip replacement surgery at AZ Sint-Jan (Brugge, Belgium) to assess patients' basic knowledge regarding PND.


Eligibility Criteria:
Inclusion Criteria:

* age 65 and above
* ASA score 1 to 3
* scheduled for elective hip surgery.

Exclusion Criteria:

* insufficient knowledge of Dutch
* known neuropsychiatric conditions
Effect of Ginseol Kg1 on Blood Pressure Lowering

In this study, we investigate the effects of Ginseol Kg1 (Korea red ginseng extract) on blood pressure in prehypertensive or stage I hypertensive patients.

This is a multicenter, randomized, placebo-controlled, double-blind study. At the end of an initial 2-week washout period, patients fulfilling the inclusion criteria are assigned to three groups, i.e. control group (placebo), low dose Ginseol Kg1 group (100mg), or high dose Ginseol Kg1 (300mg) group. They will intake the study drug for 8 weeks. 24-h ambulatory BP monitoring (ABPM) and pulse wave velocity are measured at the end of the washout period and after 8 weeks of active treatment. At each visit, seated SBP and DBP, heart rate, use of concomitant medication and spontaneously reported adverse events are recorded. Compliance with medication (determined by counting returned tablets) is evaluated at each visit.

Eligibility Criteria:
Inclusion Criteria:

* Age: Adults over 20 years
* Prehypertension or stage 1 hypertension (systolic blood pressure 120\~159mmHg or diastolic blood pressure 80\~99mmHg)
* Subject who has not taken medications to treat hypertension within 15 days prior to first visit

Exclusion Criteria:

* Subject who has been involved in other clinical trials within 30 days prior to first visit
* Subject who has following diseases within 2 years prior to screening: angina pectoris, myocardial infarction, heart failure, peripheral vascular disease, chronic liver failure, chronic renal failure, diabetes mellitus, hyperthyroidism, hypothyroidism, malignant tumor, mental disease
* Systolic blood pressure ≥ 160mmHg or diastolic blood pressure ≥ 100 mmHg during screening period
* Subject who has hepatic dysfunction(AST, ALT ≥ 2.5 times higher than normal value)
* Subject who has renal dysfunction(creatinine ≥ 1.5 times higher than normal value)
* Subject who is pregnant or breast feeding
* Alcoholic
* Subject who has an allergy to the ingredients of study product
Olmesartan Medoxomil Versus Losartan in Patients With Hypertension

The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Diastolic BP 95 mm Hg - 114 mm Hg inclusive
* No participation in any clinical trial for the last 3 months

Exclusion Criteria:

* Secondary hypertension
* Malignant hypertension
* Severe arterial hypertension
* Significant cardiovascular disease
* History or clinical evidence of cerebrovascular, gastrointestinal, hematological, hepatic disease, myocardial infarction, or severe liver disorder
* Clinical evidence of renal disease, poorly controlled diabetes, known malabsorption syndromes, psychiatric/emotional problems
Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents

The purpose of this study is to compare the efficacy and tolerability between clopidogrel resinate and clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD equivalents.


Eligibility Criteria:
Inclusion Criteria:

* Korean men and women aged 20 to 85 years with coronary heart disease (CHD) or CHD equivalent patients
* Atherosclerotic plaques in coronary computed tomography (CT) or angiography or
* History of PCI or coronary artery bypass graft surgery (CABG) \> one year or
* Diabetes mellitus (including type I and type II) or
* Confirmed carotid atherosclerotic plaque with sonography, CT or angiography or
* History of peripheral artery disease or
* History of cerebrovascular disease

Exclusion Criteria:

* Patients who had history of PCI within one year
* Patients who used concomitant anticoagulants
* Patients who had hypersensitivity to aspirin or clopidogrel, serious bleeding tendency, history of intracranial hemorrhage, sign of active bleeding, uncontrolled hypertension
* Chronic alcoholism or drug addiction
* Women who were pregnant or breastfeeding or who were not using an effective method of contraception
* The use of glycoprotein IIb/IIIa inhibitor, daily NSAIDs, lipid lowering agent (except atorvastatin), or substances with possible interactions with the study drug